Literature DB >> 26739329

Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study.

Kuan-Yi Wu1, Chia-Yih Liu1, Cheng-Sheng Chen2, Chia-Hsiang Chen1, Ing-Tsung Hsiao3,4, Chia-Ju Hsieh3,4, Chin-Pang Lee1, Tzu-Chen Yen3,4, Kun-Ju Lin5,6.   

Abstract

PURPOSE: The objective of this study was to evaluate the amyloid burden, as assessed by (18)F-florbetapir (AV-45/Amyvid) positron emission tomography PET, in patients with major depressive disorder (MDD) with different subtypes of mild cognitive impairment (MCI) and the relationship between amyloid burden and cognition in MDD patients.
METHODS: The study included 55 MDD patients without dementia and 21 healthy control subjects (HCs) who were assessed using a comprehensive cognitive test battery and (18)F-florbetapir PET imaging. The standardized uptake value ratios (SUVR) in eight cortical regions using the whole cerebellum as reference region were determined and voxel-wise comparisons between the HC and MDD groups were performed. Vascular risk factors, serum homocysteine level and the apolipoprotein E (ApoE) genotype were also determined.
RESULTS: Among the 55 MDD patients, 22 (40.0 %) had MCI, 12 (21.8 %) non-amnestic MCI (naMCI) and 10 (18.2 %) amnestic MCI (aMCI). The MDD patients with aMCI had the highest relative (18)F-florbetapir uptake in all cortical regions, and a significant difference in relative (18)F-florbetapir uptake was found in the parietal region as compared with that in naMCI subjects (P < 0.05) and HCs (P < 0.01). Voxel-wise analyses revealed significantly increased relative (18)F-florbetapir uptake in the MDD patients with aMCI and naMCI in the frontal, parietal, temporal and occipital areas (P < 0.005). The global cortical SUVR was significantly negatively correlated with MMSE score (r = -0.342, P = 0.010) and memory function (r = -0.328, P = 0.015). The negative correlation between the global SUVR and memory in the MDD patients remained significant in multiple regression analyses that included age, educational level, ApoE genotype, and depression severity (β = -3.607, t = -2.874, P = 0.006).
CONCLUSION: We found preliminary evidence of brain beta-amyloid deposition in MDD patients with different subtypes of MCI. Our findings in MDD patients support the hypothesis that a higher amyloid burden is associated with a poorer memory performance. We also observed a high prevalence of MCI among elderly depressed patients, and depressed patients with MCI exhibited heterogeneously elevated (18)F-florbetapir retention as compared with depressed patients without MCI. The higher amyloid burden in the aMCI patients suggests that these patients may also be more likely to develop Alzheimer's disease than other patients diagnosed with major depression.

Entities:  

Keywords:  18F-Florbetapir (AV-45/Amyvid); Alzheimer’s disease; Amyloid; Dementia; Major depressive disorder; Mild cognitive impairment

Mesh:

Substances:

Year:  2016        PMID: 26739329     DOI: 10.1007/s00259-015-3291-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  48 in total

Review 1.  History of depression as a risk factor for dementia: an updated review.

Authors:  A F Jorm
Journal:  Aust N Z J Psychiatry       Date:  2001-12       Impact factor: 5.744

Review 2.  Mild cognitive impairment.

Authors:  Serge Gauthier; Barry Reisberg; Michael Zaudig; Ronald C Petersen; Karen Ritchie; Karl Broich; Sylvie Belleville; Henry Brodaty; David Bennett; Howard Chertkow; Jeffrey L Cummings; Mony de Leon; Howard Feldman; Mary Ganguli; Harald Hampel; Philip Scheltens; Mary C Tierney; Peter Whitehouse; Bengt Winblad
Journal:  Lancet       Date:  2006-04-15       Impact factor: 79.321

3.  PET of brain amyloid and tau in mild cognitive impairment.

Authors:  Gary W Small; Vladimir Kepe; Linda M Ercoli; Prabha Siddarth; Susan Y Bookheimer; Karen J Miller; Helen Lavretsky; Alison C Burggren; Greg M Cole; Harry V Vinters; Paul M Thompson; S-C Huang; N Satyamurthy; Michael E Phelps; Jorge R Barrio
Journal:  N Engl J Med       Date:  2006-12-21       Impact factor: 91.245

4.  Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.

Authors:  Gaël Chételat; Victor L Villemagne; Kerryn E Pike; Kathryn A Ellis; Pierrick Bourgeat; Gareth Jones; Graeme J O'Keefe; Olivier Salvado; Cassandra Szoeke; Ralph N Martins; David Ames; Colin L Masters; Christopher C Rowe
Journal:  Brain       Date:  2011-02-09       Impact factor: 13.501

5.  Perfusion-like template and standardized normalization-based brain image analysis using 18F-florbetapir (AV-45/Amyvid) PET.

Authors:  Ing-Tsung Hsiao; Chin-Chang Huang; Chia-Ju Hsieh; Shiaw-Pyng Wey; Mei-Ping Kung; Tzu-Chen Yen; Kun-Ju Lin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-15       Impact factor: 9.236

6.  Evaluating storage, retention, and retrieval in disordered memory and learning.

Authors:  H Buschke; P A Fuld
Journal:  Neurology       Date:  1974-11       Impact factor: 9.910

7.  Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease.

Authors:  Kooresh Shoghi-Jadid; Gary W Small; Eric D Agdeppa; Vladimir Kepe; Linda M Ercoli; Prabha Siddarth; Stephen Read; Nagichettiar Satyamurthy; Andrej Petric; Sung-Cheng Huang; Jorge R Barrio
Journal:  Am J Geriatr Psychiatry       Date:  2002 Jan-Feb       Impact factor: 4.105

8.  Persistence of neuropsychologic deficits in the remitted state of late-life depression.

Authors:  Rishi K Bhalla; Meryl A Butters; Benoit H Mulsant; Amy E Begley; Michelle D Zmuda; Beth Schoderbek; Bruce G Pollock; Charles F Reynolds; James T Becker
Journal:  Am J Geriatr Psychiatry       Date:  2006-05       Impact factor: 4.105

9.  GMP-compliant automated synthesis of [(18)F]AV-45 (Florbetapir F 18) for imaging beta-amyloid plaques in human brain.

Authors:  Cheng-Hsiang Yao; Kun-Ju Lin; Chi-Chang Weng; Ing-Tsung Hsiao; Yi-Shu Ting; Tzu-Chen Yen; Tong-Rong Jan; Daniel Skovronsky; Mei-Ping Kung; Shiaw-Pyng Wey
Journal:  Appl Radiat Isot       Date:  2010-07-07       Impact factor: 1.513

10.  Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease.

Authors:  Kerryn E Pike; Greg Savage; Victor L Villemagne; Steven Ng; Simon A Moss; Paul Maruff; Chester A Mathis; William E Klunk; Colin L Masters; Christopher C Rowe
Journal:  Brain       Date:  2007-10-10       Impact factor: 13.501

View more
  12 in total

Review 1.  Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias.

Authors:  A Del Sole; S Malaspina; Alberto Magenta Biasina
Journal:  Funct Neurol       Date:  2016 Oct/Dec

2.  Decreased Cerebral Amyloid-β Depositions in Patients With a Lifetime History of Major Depression With Suspected Non-Alzheimer Pathophysiology.

Authors:  Kuan-Yi Wu; Kun-Ju Lin; Chia-Hsiang Chen; Chia-Yih Liu; Yi-Ming Wu; Cheng-Sheng Chen; Tzu-Chen Yen; Ing-Tsung Hsiao
Journal:  Front Aging Neurosci       Date:  2022-05-26       Impact factor: 5.702

3.  Excess tau PET ligand retention in elderly patients with major depressive disorder.

Authors:  Sho Moriguchi; Keisuke Takahata; Hitoshi Shimada; Manabu Kubota; Soichiro Kitamura; Yasuyuki Kimura; Kenji Tagai; Ryosuke Tarumi; Hajime Tabuchi; Jeffrey H Meyer; Masaru Mimura; Kazunori Kawamura; Ming-Rong Zhang; Shigeo Murayama; Tetsuya Suhara; Makoto Higuchi
Journal:  Mol Psychiatry       Date:  2020-07-01       Impact factor: 15.992

4.  Association of Cerebral Amyloidosis, Blood Pressure, and Neuronal Injury with Late-Life Onset Depression.

Authors:  Min Soo Byun; Young Min Choe; Bo Kyung Sohn; Dahyun Yi; Ji Young Han; Jinsick Park; Hyo Jung Choi; Hyewon Baek; Jun Ho Lee; Hyun Jung Kim; Yu Kyeong Kim; Eun Jin Yoon; Chul-Ho Sohn; Jong Inn Woo; Dong Young Lee
Journal:  Front Aging Neurosci       Date:  2016-10-13       Impact factor: 5.750

5.  Vascular depression consensus report - a critical update.

Authors:  Howard J Aizenstein; Andrius Baskys; Maura Boldrini; Meryl A Butters; Breno S Diniz; Manoj Kumar Jaiswal; Kurt A Jellinger; Lev S Kruglov; Ivan A Meshandin; Milija D Mijajlovic; Guenter Niklewski; Sarah Pospos; Keerthy Raju; Kneginja Richter; David C Steffens; Warren D Taylor; Oren Tene
Journal:  BMC Med       Date:  2016-11-03       Impact factor: 8.775

6.  Beta-amyloid deposition in patients with major depressive disorder with differing levels of treatment resistance: a pilot study.

Authors:  Peng Li; Ing-Tsung Hsiao; Chia-Yih Liu; Chia-Hsiang Chen; She-Yao Huang; Tzu-Chen Yen; Kuan-Yi Wu; Kun-Ju Lin
Journal:  EJNMMI Res       Date:  2017-03-21       Impact factor: 3.138

7.  Plasma Aβ analysis using magnetically-labeled immunoassays and PET 18F-florbetapir binding in non-demented patients with major depressive disorder.

Authors:  Kuan-Yi Wu; Ing-Tsung Hsiao; Chia-Hsiang Chen; Chia-Yih Liu; Jung-Lung Hsu; Sheng-Yao Huang; Tzu-Chen Yen; Kun-Ju Lin
Journal:  Sci Rep       Date:  2018-02-09       Impact factor: 4.379

8.  Diversity of neurodegenerative pathophysiology in nondemented patients with major depressive disorder: Evidence of cerebral amyloidosis and hippocampal atrophy.

Authors:  Kuan-Yi Wu; Kun-Ju Lin; Chia-Hsiang Chen; Cheng-Sheng Chen; Chia-Yih Liu; Sheng-Yao Huang; Tzu-Chen Yen; Ing-Tsung Hsiao
Journal:  Brain Behav       Date:  2018-06-21       Impact factor: 2.708

9.  Tau PET With 18F-THK-5351 Taiwan Patients With Familial Alzheimer's Disease With the APP p.D678H Mutation.

Authors:  Chin-Chang Huang; Ing-Tsung Hsiao; Chu-Yun Huang; Yi-Ching Weng; Kuo-Lun Huang; Chi-Hung Liu; Ting-Yu Chang; Hsiu-Chuan Wu; Tzu-Chen Yen; Kun-Ju Lin
Journal:  Front Neurol       Date:  2019-05-22       Impact factor: 4.003

10.  Whole Brain Voxel-Wise Analysis of Cerebral Retention of Beta-Amyloid in Cognitively Normal Older Adults Using 18F-Florbetaben.

Authors:  Yoo Hyun Um; Woo Hee Choi; Won Sang Jung; Young Ha Park; Chang-Uk Lee; Hyun Kook Lim
Journal:  Psychiatry Investig       Date:  2017-11-07       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.